BPG is committed to discovery and dissemination of knowledge
Cited by in CrossRef
For: De Stefano A, Carlomagno C. Beyond KRAS: Predictive factors of the efficacy of anti-EGFR monoclonal antibodies in the treatment of metastatic colorectal cancer. World J Gastroenterol 2014; 20(29): 9732-9743 [PMID: 25110411 DOI: 10.3748/wjg.v20.i29.9732]
URL: https://www.wjgnet.com/1007-9327/full/v20/i29/9732.htm
Number Citing Articles
1
Andrew Dean, Aisling Byrne, Mira Marinova, Ingrid Hayden. Clinical Outcomes of Patients with Rare and Heavily Pretreated Solid Tumors Treated according to the Results of Tumor Molecular ProfilingBioMed Research International 2016; 2016: 1 doi: 10.1155/2016/4627214
2
Maxime Guéguinou, Thomas Harnois, David Crottes, Arnaud Uguen, Nadine Deliot, Audrey Gambade, Aurélie Chantôme, Jean Pierre Haelters, Paul Alain Jaffrès, Marie Lise Jourdan, Günther Weber, Olivier Soriani, Philippe Bougnoux, Olivier Mignen, Nicolas Bourmeyster, Bruno Constantin, Thierry Lecomte, Christophe Vandier, Marie Potier-Cartereau. SK3/TRPC1/Orai1 complex regulates SOCE-dependent colon cancer cell migration: a novel opportunity to modulate anti-EGFR mAb action by the alkyl-lipid OhmlineOncotarget 2016; 7(24): 36168 doi: 10.18632/oncotarget.8786
3
Ana Bela Sarmento-Ribeiro, Andreas Scorilas, Ana Cristina Gonçalves, Thomas Efferth, Ioannis P. Trougakos. The emergence of drug resistance to targeted cancer therapies: Clinical evidenceDrug Resistance Updates 2019; 47: 100646 doi: 10.1016/j.drup.2019.100646
4
Sarah Wedden, Keith Miller, Ian M. Frayling, Teresa Thomas, Alina Chefani, Karolina Miller, Angela Hamblin, Jenny C. Taylor, Corrado D’Arrigo. Colorectal Cancer Stratification in the Routine Clinical Pathway: A District General Hospital ExperienceApplied Immunohistochemistry & Molecular Morphology 2019; 27(6): e54 doi: 10.1097/PAI.0000000000000631
5
Mariamena Arbitrio, Maria Teresa Di Martino, Francesca Scionti, Giuseppe Agapito, Pietro Hiram Guzzi, Mario Cannataro, Pierfrancesco Tassone, Pierosandro Tagliaferri. DMET™ (Drug Metabolism Enzymes and Transporters): a pharmacogenomic platform for precision medicineOncotarget 2016; 7(33): 54028 doi: 10.18632/oncotarget.9927
6
SHUN-ICHI SUZUKI, SATOSHI MATSUSAKA, MITSUHARU HIRAI, HARUMI SHIBATA, KOICHI TAKAGI, NOBUYUKI MIZUNUMA, KIYOHIKO HATAKE. A novel approach to detect KRAS/BRAF mutation for colon cancer: Highly sensitive simultaneous detection of mutations and simple pre-treatment without DNA extractionInternational Journal of Oncology 2015; 47(1): 97 doi: 10.3892/ijo.2015.2978
7
J.H.L. Neumann, A. Jung, T. Kirchner. Molekulare Pathologie des kolorektalen KarzinomsDer Pathologe 2015; 36(2): 137 doi: 10.1007/s00292-015-0005-3
8
William A. Hammond, Abhisek Swaika, Kabir Mody. Pharmacologic resistance in colorectal cancer: a reviewTherapeutic Advances in Medical Oncology 2016; 8(1): 57 doi: 10.1177/1758834015614530
9
Vivien Hichert, Catharina Scholl, Michael Steffens, Tanusree Paul, Christian Schumann, Stefan Rüdiger, Stefan Boeck, Volker Heinemann, Volker Kächele, Thomas Seufferlein, Julia Stingl. Predictive blood plasma biomarkers for EGFR inhibitor-induced skin rashOncotarget 2017; 8(21): 35193 doi: 10.18632/oncotarget.17060
10
Anna M. Valentini, Elisabetta Cavalcanti, Marianna Di Maggio, Maria L. Caruso. RAS-expanded Mutations and HER2 Expression in Metastatic Colorectal Cancer: A New Step of Precision MedicineApplied Immunohistochemistry & Molecular Morphology 2018; 26(8): 539 doi: 10.1097/PAI.0000000000000475
11
P. Reijonen, P. Österlund, H. Isoniemi, J. Arola, A. Nordin. Histologically Verified Biliary Invasion was Associated with Impaired Liver Recurrence-Free Survival in Resected Colorectal Cancer Liver MetastasesScandinavian Journal of Surgery 2019; 108(3): 201 doi: 10.1177/1457496918812237
12
Nathaniel Edward Bennett Saidu, Marie Bretagne, Audrey Lupo Mansuet, Pierre-Alexandre Just, Karen Leroy, Olivier Cerles, Sandrine Chouzenoux, Carole Nicco, Diane Damotte, Marco Alifano, Bruno Borghese, François Goldwasser, Frédéric Batteux, Jérôme Alexandre. Dimethyl fumarate is highly cytotoxic in KRAS mutated cancer cells but spares non-tumorigenic cellsOncotarget 2018; 9(10): 9088 doi: 10.18632/oncotarget.24144
13
Serena Bonin. Is it Possible to Predict Benefit from 5FU Adjuvant Therapy in Stage III Colon Cancer Patients?EBioMedicine 2015; 2(8): 780 doi: 10.1016/j.ebiom.2015.06.011
14
Jens H.L. Neumann, Andreas Jung, Thomas Kirchner. Molekulare Pathologie des kolorektalen KarzinomsWiener klinisches Magazin 2015; 18(4): 140 doi: 10.1007/s00740-015-0061-6
15
D. S. Mikhailenko, G. D. Efremov, N. Yu. Safronova, V. V. Strelnikov, B. Ya. Alekseev. Detection of Rare Mutations by Routine Analysis of KRAS, NRAS, and BRAF OncogenesBulletin of Experimental Biology and Medicine 2017; 162(3): 375 doi: 10.1007/s10517-017-3619-z
16
Kiyoko Takane, Kiwamu Akagi, Masaki Fukuyo, Koichi Yagi, Tadatoshi Takayama, Atsushi Kaneda. DNA methylation epigenotype and clinical features ofNRAS-mutation(+) colorectal cancerCancer Medicine 2017; 6(5): 1023 doi: 10.1002/cam4.1061
17
Giorgio Stanta, Stephan Wenzel Jahn, Serena Bonin, Gerald Hoefler. Tumour heterogeneity: principles and practical consequencesVirchows Archiv 2016; 469(4): 371 doi: 10.1007/s00428-016-1987-9
18
Krizelle Mae M. Alcantara, Joshua Reginald P. Malapit, Ryan Timothy D. Yu, Jose Antonio Ma. G. Garrido, John Paul T. Rigor, Arlou Kristina J. Angeles, Eva Maria Cutiongco-de la Paz, Reynaldo L. Garcia. Non-Redundant and Overlapping Oncogenic Readouts of Non-Canonical and Novel Colorectal Cancer KRAS and NRAS MutantsCells 2019; 8(12): 1557 doi: 10.3390/cells8121557
19
Youngchul Kim, Daewon Kim, Biwei Cao, Rodrigo Carvajal, Minjung Kim. PDXGEM: patient-derived tumor xenograft-based gene expression model for predicting clinical response to anticancer therapy in cancer patientsBMC Bioinformatics 2020; 21(1) doi: 10.1186/s12859-020-03633-z
20
Marina De Rosa, Daniela Rega, Valeria Costabile, Francesca Duraturo, Antonello Niglio, Paola Izzo, Ugo Pace, Paolo Delrio. The biological complexity of colorectal cancer: insights into biomarkers for early detection and personalized careTherapeutic Advances in Gastroenterology 2016; 9(6): 861 doi: 10.1177/1756283X16659790
21
T. Yoshino, D.C. Portnoy, R. Obermannová, G. Bodoky, J. Prausová, R. Garcia-Carbonero, T. Ciuleanu, P. García-Alfonso, A.L. Cohn, E. Van Cutsem, K. Yamazaki, S. Lonardi, K. Muro, T.W. Kim, K. Yamaguchi, A. Grothey, J. O’Connor, J. Taieb, S.R. Wijayawardana, R.R. Hozak, F. Nasroulah, J. Tabernero. Biomarker analysis beyond angiogenesis: RAS/RAF mutation status, tumour sidedness, and second-line ramucirumab efficacy in patients with metastatic colorectal carcinoma from RAISE—a global phase III studyAnnals of Oncology 2019; 30(1): 124 doi: 10.1093/annonc/mdy461